bio/acc Podcast
Jay Rosanelli is the CEO and Co-Founder of Syenex, a biotech developing a platform for in vivo gene therapy delivery. While capital in the gene and cell therapy (CGT) space has grown over the last 5 years, there remain serious bottlenecks in delivery. In this conversation, we discuss what Syenex is building, the future of CGT, and what's next in AI-driven drug discovery and neurotech. Check out what Syenex is building: https://www.syenex.com/ 0:00 Introduction 0:55 Background 4:56 Biotech Capital 11:50 The Delivery Problem 17:37 Platform vs. Therapeutics 24:08 Partnership Model31:28 In-vivo CAR-T 37:49 Economics of Platform 42:08 AI x BIo 48:19 Future of BiotechABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by @RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.
21 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der bio/acc Podcast-Community!